Company raises €1.5B for corporate purposes, including debt reduction and potential acquisitions
Boston Scientific (NYSE: BSX) has priced a public offering totaling $1.57 billion (€1.5 billion) through its Europe-based subsidiary, American Medical Systems Europe B.V. (AMS Europe). The offering includes €850 million in 3% notes due in 2031 and €650 million in 3.250% notes due in 2034, both fully guaranteed by Boston Scientific.
Key Details:
- Offering Closing Date: Expected on February 26, 2025, pending customary conditions.
- Use of Proceeds: Primarily to repay AMS Europe’s 0.75% senior notes maturing in March 2025, with the remaining funds directed toward general corporate purposes such as investments, debt reduction, and working capital.
Financial Outlook:
Boston Scientific also reported strong 2024 results, with full-year sales growth projected between 12.5% and 14.5% for 2025, underscoring the success of its innovative product portfolio and strategic initiatives, such as the Farapulse pulsed field ablation system.
Follow MEDWIRE.AI for the latest financial and strategic moves in the medtech sector.
